Sign in

Private company

IVERIC bio

American pharmaceutical preparations company based in New York City1

In its 2023 annual report the company says: “We are a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. We are committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases, including earlier stages of age-related macular degeneration, or AMD. Our lead asset is our clinical stage product candidate avacincaptad pegol, which is also referred to as ACP or Zimura®, a complement C5 inhibitor.”69 It was founded in 2007.1

Last updated Oct 21, 2026.

Overview

2007Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York City1
  • Websitewww.ophthotech.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address8 Sylvan Way, Parsippany, Nj 070544
  • Filer categoryLarge accelerated filer4
  • LEI549300GZXI59U71XPM703
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 42802663

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-50.2%Return on equity5
-$48.5MFree cash flow6

Financial statements

Revenue78$0 in 2019
0$100.0M$200.0M$300.0M2016: $50.9M$50.9M20162017: $210.0M$210.0M2017+312%2018: $0$020182019: $0$02019
Operating income7896-$61.3M in 2019−69% since 2016
-$200.0M-$100.0M0$100.0M$200.0M2016: -$195.6M-$195.6M20162017: $108.0M$108.0M20172018: -$65.3M-$65.3M20182019: -$61.3M-$61.3M2019−6%
Net income7896-$58.9M in 2019−70% since 2016
-$200.0M-$100.0M0$100.0M$200.0M2016: -$193.4M-$193.4M20162017: $114.2M$114.2M20172018: $63.1M$63.1M2018−45%2019: -$58.9M-$58.9M2019
Fiscal year2016201720182019
Revenue$50.9M7$210.0M8$08$08
Research and development$196.3M7$66.3M8$41.7M9$39.6M6
Operating expenses
Operating income-$195.6M7$108.0M8-$65.3M9-$61.3M6
Income before tax
Income tax-$406.0K7-$4.7M8-$1.1M9-$111.0K6
Net income-$193.4M7$114.2M8$63.1M9-$58.9M6
Earnings per share-$5.457$3.188$1.709-$1.396
Earnings per share (diluted)-$5.457$3.178$1.709-$1.396
Shares (weighted, basic)
Shares (weighted, diluted)

Compare IVERIC bio with another company

Corporate structure

IVERIC bio sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IVERIC bio

  • IVERIC bio New York, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IVERIC bio reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.1M5 Dec 31, 2022$1.3M5 Dec 31, 2021+54.9%
Accumulated depreciation$1.1M5 Dec 31, 2022$993.0K5 Dec 31, 2021+13.9%
Property and equipment, net$946.0K5 Dec 31, 2022$348.0K5 Dec 31, 2021+171.8%
Operating-lease assets (leased space)$1.2M5 Dec 31, 2022$1.5M5 Dec 31, 2021−22.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$476.3M5 Dec 31, 2022$261.4M5 Dec 31, 2021+82.2%
Marketable securities, current$170.5M5 Dec 31, 2022$120.3M5 Dec 31, 2021+41.8%
Debt securities available for sale$170.5M5 Dec 31, 2022$120.3M5 Dec 31, 2021+41.8%

Leadership

Who has led IVERIC bio, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David R. Guyer2013–2017
  2. Glenn Sblendorio2017–2023

Chair

  1. David R. Guyer2017–2020

President

  1. Glenn Sblendorio2017–2020
  2. Pravin Dugel2021–2023

Chief financial officer

  1. Bruce Peacock2013–2014
  2. Michael G. Atieh2014–2016
  3. Glenn Sblendorio2016–2017
  4. David Francis Carroll2017–2023

Chief operating officer

  1. Glenn Sblendorio2016–2017
  2. Keith Westby2017–2023
2010201520202025
Board members and other officers (19)

Former names

  • Ophthotech Corp.Aug 24, 2007 to Apr 11, 20194

Timeline

  1. Jul 11, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer42
  2. Jul 6, 20238-K Shareholder vote43
  3. May 23, 20238-K Executive or director change; Shareholder vote44
  4. May 1, 20238-K Entered a material agreement; Bylaws or fiscal year changed; Other events45
  5. Mar 20, 20238-K Entered a material agreement46
  6. Mar 10, 20238-K Other events47
  7. Mar 1, 20238-K Results of operations48
  8. Jan 6, 20238-K Results of operations; Executive or director change; Other events49
  9. Dec 27, 20228-K Entered a material agreement50
  10. Dec 12, 20228-K New debt or obligation51
  11. Dec 5, 20228-K Entered a material agreement; Other events52
  12. Nov 28, 20228-K Other events53
  13. Jul 5, 2017New chief executive Glenn Sblendorio becomes CEO14
  14. Sep 24, 2013New chief executive David R. Guyer becomes CEO15
  15. 2007Founded Founded1

Calendar

When it reported results

  1. Mar 1, 2023Reported quarterly or annual results48
  2. Jan 6, 2023Reported quarterly or annual results49
  3. Nov 3, 2022Reported quarterly or annual results54
  4. Jul 26, 2022Reported quarterly or annual results55
  5. May 4, 2022Reported quarterly or annual results56
  6. Feb 24, 2022Reported quarterly or annual results57
  7. Nov 9, 2021Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

229 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 30 major events, 116 insider forms, 20 large holders, 56 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Jul 21, 202315-12G EDGAR
  3. Jul 17, 2023EFFECT EDGAR
  4. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  5. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  6. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  7. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  8. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  9. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  10. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  11. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  12. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  13. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  14. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  15. Jul 13, 20234 OWNERSHIP DOCUMENT EDGAR
  16. Jul 11, 2023S-8 POS EDGAR
  17. Jul 11, 2023S-8 POS EDGAR
  18. Jul 11, 2023S-8 POS EDGAR
  19. Jul 11, 2023S-8 POS EDGAR
  20. Jul 11, 2023S-8 POS EDGAR

The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

67 open-market trades by officers, directors and large owners since October 2021: 2 buys and 65 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 3, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$39.45$789.0KForm 4
Jun 2, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$37.87$757.4KForm 4
May 2, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$37.81$756.2KForm 4
May 1, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$37.12$742.4KForm 4
May 1, 2023Carroll David FrancisSVP, Chief Financial OfficerSale63,500$37.04$2.4MForm 4
Apr 24, 2023Carroll David FrancisSVP, Chief Financial OfficerSale48,171$30.21$1.5MForm 4
Apr 24, 2023Westby KeithSVP, Chief Operating OfficerSale18,782$30.07$564.8KForm 4
Apr 21, 2023Carroll David FrancisSVP, Chief Financial OfficerSale1,829$30.00$54.9KForm 4
Apr 21, 2023Westby KeithSVP, Chief Operating OfficerSale1,218$30.00$36.5KForm 4
Apr 3, 2023Westby KeithSVP, Chief Operating OfficerSale40,000$26.70$1.1MForm 4
Mar 2, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$23.93$478.6KForm 4
Feb 17, 2023Westby KeithSVP, Chief Operating OfficerSale15,000$25.05$375.8KForm 4
Feb 2, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$23.82$476.4KForm 4
Feb 1, 2023Westby KeithSVP, Chief Operating OfficerSale20,000$23.03$460.6KForm 4
Jan 3, 2023Westby KeithSVP, Chief Operating OfficerSale3,480$20.06$69.8KForm 4
Jan 3, 2023SBLENDORIO GLENNChief Executive OfficerSale17,447$20.06$350.0KForm 4
Jan 3, 2023Carroll David FrancisSVP, Chief Financial OfficerSale3,602$20.06$72.3KForm 4
Jan 3, 2023Simms Christopher PaulSVP, Chief Commercial OfficerSale2,368$20.06$47.5KForm 4
Dec 19, 2022SBLENDORIO GLENNChief Executive OfficerSale19,457$21.51$418.5KForm 4
Dec 19, 2022Westby KeithSVP, Chief Operating OfficerSale6,740$21.51$145.0KForm 4

All 67 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How IVERIC bio is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIVERIC bio, Inc.2
  • CIK0001410939
  • Employer ID (EIN)20-81853472
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address8 Sylvan Way, Parsippany, NJ 070542
  • Phone(609) 474-67552
  • Shares outstanding137,782,748 as of May 1, 202312
  • Public float$1.1B as of Jun 30, 20225
  • On EDGAR sinceAug 24, 20072
  • Filings852 in all: 4 (371), 8-K (132), SC 13G/A (54), SC 13G (31), 10-Q (29), 3 (28), DEFA14A (19), S-8 (17)2
    All 51 form types

    S-8 POS (17), CT ORDER (15), SC 13D/A (15), 424B5 (11), CORRESP (11), 10-K (10), DEF 14A (10), EFFECT (9), UPLOAD (9), D (7), 144 (4), S-1/A (4), S-3 (4), SC 13D (4), 424B3 (3), 8-K/A (3), POS AM (3), 424B4 (2), ARS (2), FWP (2), S-1 (2), S-3/A (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 424B1 (1), 5 (1), 8-A12B (1), CERTNAS (1), DEFM14A (1), DRS (1), POSASR (1), PRE 14A (1), PREM14A (1), REGDEX (1), REGDEX/A (1), S-1MEF (1), S-3ASR (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2023
    Quarterly report (10-Q) May 10, 2023
    Proxy statement (DEF 14A) Apr 5, 2023
    Latest 8-K (8-K) Jul 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
    SEC EDGAROther events
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69